RATIONALE: Movement disorders such as disturbances of fine motor co-ordination are a frequent phenomenon in patients with obsessive-compulsive disorder (OCD). OBJECTIVES: Our aim was to investigate changes of hand-motor dysfunction in OCD patients under the influence of 10-week treatment with sertraline and behaviour therapy. METHODS: We examined the performance of 40 patients satisfying DSM-IV criteria for OCD before and under this therapy using a digitising tablet and kinematic analysis of handwriting and drawing movements. Forty healthy controls were also tested (test-retest interval: 10 weeks). RESULTS: The speed of drawing was significantly lower in OCD patients than in controls (mean+/-standard deviation=197.03+/-113.26 mm/s for patients and 182.48+/-189.61 mm/s for controls; P=0.01). After 10 weeks of therapy, this parameter normalised in patients (from 197.03+/-113.26 mm/s to 163.66+/-101.92 mm/s; P=0.001). CONCLUSIONS: Hand-motor dysfunction (especially bradykinesia) improves with a serotonin-enhancing therapy in OCD patients.
RATIONALE: Movement disorders such as disturbances of fine motor co-ordination are a frequent phenomenon in patients with obsessive-compulsive disorder (OCD). OBJECTIVES: Our aim was to investigate changes of hand-motor dysfunction in OCDpatients under the influence of 10-week treatment with sertraline and behaviour therapy. METHODS: We examined the performance of 40 patients satisfying DSM-IV criteria for OCD before and under this therapy using a digitising tablet and kinematic analysis of handwriting and drawing movements. Forty healthy controls were also tested (test-retest interval: 10 weeks). RESULTS: The speed of drawing was significantly lower in OCDpatients than in controls (mean+/-standard deviation=197.03+/-113.26 mm/s for patients and 182.48+/-189.61 mm/s for controls; P=0.01). After 10 weeks of therapy, this parameter normalised in patients (from 197.03+/-113.26 mm/s to 163.66+/-101.92 mm/s; P=0.001). CONCLUSIONS:Hand-motor dysfunction (especially bradykinesia) improves with a serotonin-enhancing therapy in OCDpatients.
Authors: P Mavrogiorgou; R Mergl; P Tigges; J El Husseini; A Schröter; G Juckel; M Zaudig; U Hegerl Journal: J Neurol Neurosurg Psychiatry Date: 2001-05 Impact factor: 10.154
Authors: E Hollander; E Schiffman; B Cohen; M A Rivera-Stein; W Rosen; J M Gorman; A J Fyer; L Papp; M R Liebowitz Journal: Arch Gen Psychiatry Date: 1990-01
Authors: W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney Journal: Arch Gen Psychiatry Date: 1989-11
Authors: Sergei Mechtcheriakov; Ivo W Graziadei; André Kugener; Ingrid Schuster; Joerg Mueller; Hartmann Hinterhuber; Wolfgang Vogel; Josef Marksteiner Journal: J Neurol Date: 2005-10-28 Impact factor: 4.849
Authors: Igor Elman; Tamara V Gurvits; Evelyne Tschibelu; Justin D Spring; Natasha B Lasko; Roger K Pitman Journal: PLoS One Date: 2013-04-04 Impact factor: 3.240